Ralph V. Boccia, MD
Advertisement
Ralph V. Boccia, MD, is the founder of The Center for Cancer and Blood Disorders and board-certified in medical oncology, hematology and internal medicine.
Articles by Ralph V. Boccia, MD
Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.
Advertisement
Latest Updated Articles
Case Impressions: 66-Year-Old Man With mCSPCPublished: December 2nd 2020 | Updated:
- AR-Targeted Therapy for mCSPC: Monitoring for Progression
Published: December 2nd 2020 | Updated:
- Frontline Therapy for mCSPC
Published: December 2nd 2020 | Updated:
- AR-Targeted Therapy for mCSPC: Adverse Events
Published: December 2nd 2020 | Updated:
- mCSPC: Incorporating Newer Therapies Into Practice
Published: December 2nd 2020 | Updated:
- The TITAN Trial in mCSPC
Published: December 2nd 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5